

NAMSDL



National Alliance for Model State Drug Laws

BILL STATUS – CARRYOVER, 2012 AND SPECIAL SESSIONS CATHINONE DERIVATIVES

© 2011 Research is current as of February 27, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

<u>State</u>	<u>Bill No.</u>	<u>Brief Description</u>	<u>Status</u>	<u>Date of Last Action</u>
Alabama	H.B. 158	adds methylone, MDPV, mephedrone, methedrone, 3-FMC, 4-FMC	Passed House; in Senate committee	2/23/2012
Alabama	S.B. 208	adds methylone, MDPV, mephedrone, methedrone, 3-FMC, 4-FMC	Passed Senate; in House committee	2/23/2012
Alaska	S.B. 140	adds MDPV, mephedrone, generic language	Referred to committee	2/13/2012
Alaska	H.B. 253	adds MDPV, mephedrone, generic language	Referred to committee	2/10/2012
Arizona	S.B. 1043	adds fluoromethcathinone, butylone, MDPV, methylmethcathinone, methoxymethcathinone, NRG-1, methylone	Passed Senate; referred to House	1/19/2012
Arizona	H.B. 2356	adds fluoromethcathinone, butylone, MDPV, methylmethcathinone, methoxymethcathinone, NRG-1, methylone	Signed by Governor	2/17/2012
Colorado	S.B. 116	adds metamfepramone, ethcathinone, a-PPP, buphedrone, a-PBP, a-PVP, mephedrone, MaPPP, MPBP, methedrone, MOPPP, fluoromethcathinone, methylone, MDPPP, MDPV, NRG-1	Referred to Appropriations	2/21/2012
D.C.	L.B. B19-645	adds BZP, ephedrone, MDPV, mephedrone	Hearing set for 3/16/2012	1/13/2012
D.C.	L.B. B19-631	adds MDPV, mephedrone, methylone, methedrone, 3-fluoromethcathinone, 4-fluoromethcathinone	Hearing set for 3/16/2012	12/30/2011
Delaware	S.B. 160	adds 3-fluoromethcathinone, 4-fluoromethcathinone, a-PPP, a-PVP, BZ-6378, butylone, ephedrone, ethcathinone, ethylone, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1	Signed by Governor	1/25/2012
Florida	H.B. 1175	adds buphedrone, butylone, BZP, ethcathinone, ethylone, eutylone, MDPBP, MDPPP, MOPPP, NRG-1, pentylone, a-PBP, a-PVP, a-PPP, MaPPP	Passed House; in Senate committee	2/23/2012
Florida	S.B. 1502	adds buphedrone, butylone, BZP, ethcathinone, ethylone, eutylone, MDPBP, MDPPP, MOPPP, NRG-1, pentylone, a-PBP, a-PVP, a-PPP, MaPPP	Committee substitute read first time	2/21/2012
Georgia	S.B. 445	Adds BZP, 4-fluoromethcathinone,	Read and	2/16/2012

© 2011 Research is current as of February 27, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

		methylone, mephedrone, methedrone, MDPV	referred to committee	
Hawaii	H.B. 2600	adds mephedrone, MDPV, methylone, generic language	Committee recommends pass with amendments	2/23/2012
Indiana	S.B. 26	adds fluoromethcathinone, 4-EMC, MDPV, mephedrone, methedrone, methylone	Passed House; returned to Senate with amendments	2/20/2012
Indiana	H.B. 1196	adds MPBP, a-PPP, a-PVP, buphedrone, butylone, 2-DPMP, ethylone, eutylone, 4-fluoromethcathinone, MDAI, NRG-1, pentedrone, pentylone, generic language	Committee report to pass adopted	2/23/2012
Indiana	S.B. 234	adds MPBP, MDPV, a-PPP, a-PVP, buphedrone, butylone, 2-DPMP, ethylone, eutylone, 4-fluoromethcathinone, MDAI, NRG-1, pentedrone, pentylone, generic language	Passed House; returned to Senate with amendments	2/21/2012
Iowa	H.S.B. SB609	adds mephedrone, MDPV, methylone, NRG-1, methedrone, ethcathinone, ethylone, butylone, metamfepramone, a-PPP, MOPPP, MDPPP, a-PVP, MDAI, 3-FMC, 4-FMC, MPBP	Voted – Public Safety	2/23/2012
Iowa	S.S.B. SB3104	adds mephedrone, MDPV, methylone, NRG-1, methedrone, ethcathinone, ethylone, butylone, metamfepramone, a-PPP, MOPPP, MDPPP, a-PVP, MDAI, 3-FMC, 4-FMC, MPBP	Filed	1/30/2012
Kentucky	H.B. 176	adds buphedrone, BZP, ethcathinone, generic language	Referred to committee	1/4/2012
Kentucky	H.B. 185	adds buphedrone, BZP, ethcathinone, generic language	Referred to committee	1/4/2012
Kentucky	S.B. 173	Adds buphedrone, ethcathinone, BZP, generic language	Introduced	2/24/2012
Maryland	H.B. 589	adds methylone, MDPV, mephedrone, methedrone, 4-fluoromethcathinone, 3-fluoromethcathinone	Hearing set for 3/6 at 1pm	2/10/2012
Massachusetts	S.B. 2122	adds methylone, MDPV, mephedrone, methedrone, 3-fluoromethcathinone, 4-fluoromethcathinone, NRG-1, butylone, methcathinone, HMMC, MPBP, ephedrone, 4-EMC, 3,4-DMMC, a-PVP, eutylone, ethylone	Passed as amended; ordered engrossed in Senate	2/2/2012
Massachusetts	S.B. 2125	adds methylone, MDPV, mephedrone,	Passed Senate;	2/6/2012

© 2011 Research is current as of February 27, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

		methedrone, 3-fluoromethcathinone, 4-fluoromethcathinone, NRG-1, butylone, methcathinone, HMMC, MPBP, ephedrone, 4-EMC, 3,4-DMMC, a-PVP, eutylone, ethylone	referred to House	
Michigan	H.B. 5250	adds 4-fluoromethcathinone, methylone	Printed bill filed	1/18/2012
Nebraska	L.B. 814	adds fluoromethcathinone, butylone, MDPV, mephedrone, methedrone, methylone, NRG-1, generic language	Placed on general file	2/2/2012
New Mexico	H.B. 93	adds a-PPP, a-PVP, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, MOPPP, NRG-1	Introduced	1/18/2012
Ohio	S.B. 301	Adds methylone, MDPV, mephedrone, methedrone, 3-fluoromethcathinone, 4-fluoromethcathinone	Introduced	2/15/2012
Rhode Island	S.B. 2154	adds fluoromethcathinone, MDPV, mephedrone, methoxymethcathinone, methylone	Introduced; referred to committee	1/18/2012
Rhode Island	H.B. 7170	adds fluoromethcathinone, MDPV, mephedrone, methoxymethcathinone, methylone	Committee recommends measure be held for further study	2/8/2012
Rhode Island	S.B. 2501	Adds methylone, MDPV, mephedrone, methoxymethcathinone, fluoromethcathinone	Introduced; referred to committee	2/16/2012
Rhode Island	H.B. 7574	Adds methylone, MDPV, mephedrone, methoxymethcathinone, fluoromethcathinone	Introduced; referred to committee	2/15/2012
South Carolina	S.B. 1056	adds 4-fluoromethcathinone, 4-MEC, buphedrone, butylone, MDPV, mephedrone, methedrone, methylone, pentedrone, pentylone, generic language	Passed Senate; referred to House committee	2/7/2012
South Carolina	H.B. 3793	adds 4-fluoromethcathinone, 4-MEC, buphedrone, butylone, MDPV, mephedrone, methedrone, methylone, pentedrone, pentylone, generic language	Passed House; referred to Senate committee	2/1/2012
South Carolina	S.B. 1005	adds 3-fluoromethcathinone, 4-fluoromethcathinone, butylone, MDPV, mephedrone, methedrone, methylone, NRG-1	Referred to subcommittee	1/9/2012
South Carolina	H.B. 4471	adds generic language	Referred to committee	1/10/2012
South Carolina	H.B.	adds generic language	Referred to	1/10/2012

© 2011 Research is current as of February 27, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

	4515		committee	
South Dakota	S.B. 23	adds 3-fluoromethcathinone, 4-fluoromethcathinone, a-PPP, a-PVP, butylone, ethcathinone, ethylone, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1, generic language	Signed by Governor	2/24/2012
Tennessee	S.B. 2507	adds methylone, MDPV, mephedrone, methedrone, HMMC, flephedrone, 3-FMC, MPBP, ephedrone, 4-EMC, 3,4-DMMC, a-PVP, NRG-1, butylone, pentylone, eutylone, ethylone, generic language	Referred to committee	1/19/2012
Tennessee	H.B. 2645	adds methylone, MDPV, mephedrone, methedrone, HMMC, flephedrone, 3-FMC, MPBP, ephedrone, 4-EMC, 3,4-DMMC, a-PVP, NRG-1, butylone, pentylone, eutylone, ethylone, generic language	Placed on subcommittee calendar for 2/28	2/22/2012
Tennessee	S.B. 2804	adds 3-fluoromethcathinone, 4-fluoromethcathinone, MDPV, mephedrone, methedrone, methylone	Referred to committee	1/26/2012
Tennessee	H.B. 2925	adds 3-fluoromethcathinone, 4-fluoromethcathinone, MDPV, mephedrone, methedrone, methylone	Assigned to subcommittee	2/8/2012
Tennessee	S.B. 2230	adds BZP	Received from Senate; held on House desk	2/16/2012
Tennessee	H.B. 2368	adds BZP	Placed on subcommittee calendar for 2/28	2/22/2012
Utah	H.B. 254	adds fluoromethcathinone, BZP	Passed House; referred to Senate committee	2/21/2012
Virginia	H.B. 986	adds 3,4-DMMC, 3-fluoromethcathinone, 4-fluoromethcathinone, 4-EMC, 4-MEC, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, methedrone, methylone, MOPPP, MaPPP, NRG-1, pentedrone, pentylone	Left in Courts of Justice	2/14/2012
Virginia	S.B. 273	adds 3,4-DMMC, 3-fluoromethcathinone, 4-fluoromethcathinone, 4-EMC, 4-MEC, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDAI, MDPPP,	Read first time; referred to House committee	2/21/2012

© 2011 Research is current as of February 27, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

		metamfepramone, methedrone, methylone, MOPPP, MaPPP, NRG-1, pentedrone, pentylone		
Virginia	S.B. 223	adds 3,4-DMMC, 3-fluoromethcathinone, 4-fluoromethcathinone, 4-EMC, 4-MEC, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, methedrone, methylone, MOPPP, MaPPP, NRG-1, pentedrone, pentylone	Incorporated into SB273	1/23/2012
Virginia	H.B. 508	adds 3,4-DMMC, 3-fluoromethcathinone, 4-fluoromethcathinone, 4-EMC, 4-MEC, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, methedrone, methylone, MOPPP, MaPPP, NRG-1, pentedrone, pentylone	Passed House; referred to Senate committee	2/22/2012
Washington	S.B. 6007	adds generic language	Referred to committee	1/9/2012
United States	S409	adds mephedrone and MDPV	Placed on Senate calendar	7/28/2011
United States	HR1571	adds mephedrone and MDPV	Referred to committee	7/11/2011
United States	HR1254	adds 3-fluoromethcathinone, 4-fluoromethcathinone, a-PPP, a-PVP, butylone, ethcathinone, ethylone, MDAI, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1	Passed House; referred to Senate committee	12/8/2011

© 2011 Research is current as of February 27, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.